Find 49 companies with promising cash flow potential yet trading below their fair value.
To own CTS, you need to believe the company can keep shifting from legacy transportation exposure toward more diversified, higher quality earnings while managing trade and geopolitical pressures. The latest results, higher sales guidance, and confirmed appetite for acquisitions support that narrative in the near term, while ongoing softness risks in transportation and certain medical lines remain the key watchpoints. The Q1 update does not materially change the biggest risk, which is end market volatility in CTS’s core segments.
The completion of the US$18.28 million buyback, alongside narrowed 2026 sales guidance of US$560 million to US$580 million, is the most relevant recent update here. Together, they frame how management is currently balancing reinvestment and capital returns while it continues to look for acquisitions that could reinforce the diversification catalyst investors are focused on.
Yet even with better guidance, investors should be aware that exposure to transportation volumes and China-related tariff risk could still...
Read the full narrative on CTS (it's free!)
CTS’ narrative projects $639.6 million revenue and $89.0 million earnings by 2029.
Uncover how CTS' forecasts yield a $58.00 fair value, a 6% downside to its current price.
Two fair value estimates from the Simply Wall St Community cluster between US$58.00 and about US$62.12 per share, underscoring how opinions can differ even in a narrow range. You should weigh those views against CTS’s reliance on transportation and medical demand, where any prolonged softness could affect how the business performs over time.
Explore 2 other fair value estimates on CTS - why the stock might be worth as much as $62.12!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com